A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-2a as first line treatment in metastatic melanoma

: Vihinen P P, Hernberg M, Vuoristo M-S, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S

: 2010

: Melanoma Research

: 4

: 20

: 4

: 318

: 325

: 8

: 0960-8931

DOI: https://doi.org/10.1097/CMR.0b013e3283390365